Aclaris Therapeutics, Inc. (ACRS)

$14.05

-0.28 (-1.95%)
Rating:
Recommendation:
Buy
Symbol ACRS
Price $14.05
Beta 0.585
Volume Avg. 0.43M
Market Cap 936.899M
Shares () -
52 Week Range 9.84-18.958
1y Target Est -
DCF Unlevered ACRS DCF ->
DCF Levered ACRS LDCF ->
ROE -39.41% Strong Sell
ROA -30.67% Strong Sell
Operating Margin -
Debt / Equity 21.74% Neutral
P/E -
P/B 4.26 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ACRS news


Dr. Neal Walker
Healthcare
Diagnostics & Research
NASDAQ Global Select

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.